This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Practical solutions for weak or absent staining, high background, overstaining and nonspecific IHC staining, with control-based checks to help distinguish technical artifacts from true expression patterns.
Consistent IHC results require more than following protocol steps. Compare the staining pattern with expected target localization and verify that positive, negative and detection-system controls behave as expected before adjusting experimental conditions.
Sample preparation, antigen retrieval, blocking, primary antibody incubation and detection each influence signal and background. When troubleshooting, check specimen and control performance first, then change one validated parameter at a time.
Use the troubleshooting tables below for common staining problems. For expanded guidance, access the Boster IHC Troubleshooting Handbook or the IHC Optimization resources.
For unexpected results, jump to false-positive/false-negative checks or control-based troubleshooting.
Download troubleshooting handbooks for IHC, Western blot and ELISA for FREE.
Troubleshooting guidesDid you know that Boster can accelerate your research projects by assisting you in antibody validation?
The following guide serves as a checklist for identifying and resolving common protocol issues encountered during IHC staining. Addressing these challenges effectively can save time, and resources, and ensure high-quality staining results.
In July 2020, our team interviewed industry experts and composed an in-depth interview for topics of optimizing and troubleshooting IHC. It answers many interesting questions and you can see more details here: Boster Interview Series: Expert Tips on IHC
Weak staining of CD3 epsilon in human tonsil tissue
Improved staining of CD3 epsilon in human tonsil tissue
Good IHC results rely on strong, specific staining of the target antigen. Weak or lack of staining often requires repeating the experiment, which can be costly in terms of time and resources. Use the table below to identify and correct the source of weak staining.
| S.No. | Possible Cause | Solution |
|---|---|---|
| 1 | Signal loss or variability in stored unstained tissue sections |
|
| 2 | The antibody has not been validated for the sample preparation and IHC application used |
|
| 3 | Fixation procedures (using formalin and paraformaldehyde fixatives) have masked the epitope that the antibody recognizes |
|
| 4 | The primary and/or secondary antibody has lost its activity due to improper storage, dilution, or excessive freezing and thawing |
|
| 5 | Insufficient deparaffinization |
|
| 6 | Limited antibody access to an intracellular or nuclear epitope |
|
| 7 | Contaminated or improperly prepared buffer may compromise reproducibility |
|
| 8 | The primary antibody and the secondary antibody are not compatible |
|
| 9 | The protein is not present in the tissue of interest or has not sufficiently expressed |
|
| 10 | Insufficient antibody to detect protein of interest |
|
| 11 | Tissues dried out |
|
| 12 | Chromogen or enzyme detection reagents are inactive, expired or incompatible |
|
| 13 | Buffer incompatible with enzyme |
|
| 14 | Inadequate antigen retrieval |
|
For a more detailed exploration of weak staining issues, check out our advanced guide on troubleshooting IHC experiments.
High background can obscure tissue features and reduce the signal-to-noise ratio. It may result from primary or secondary antibody binding, insufficient blocking, endogenous enzyme/biotin activity, tissue autofluorescence in IF, or sample preparation artifacts.
High background staining of rat brain tissue using anti-VCP antibody
Improved staining of VCP in rat brain tissue
| S.No. | Possible Cause | Solution |
|---|---|---|
| 1 | The blocking serum is incorrect |
|
| 2 |
Blocking is insufficient (Do not over-block the tissue because antigenic sites may be masked) |
|
| 3 | The primary antibody concentration is too high |
|
| 4 | Non-specific binding by secondary antibody |
|
| 5 | Endogenous peroxidase or alkaline phosphatase activity produces background in enzyme-based detection |
|
To reduce background staining further, see our in-depth high-background DAB troubleshooting guide.
Overstaining of mouse liver tissue stained with anti-SC10A1 antibody.
Improved staining of VSC10A1 in mouse liver tissue
Overstaining occurs when an increase in signal reduces contrast, making it difficult to analyze tissue structures accurately. Below are some tips to avoid overstaining.
| S.No. | Possible Cause | Solution |
|---|---|---|
| 1 | Primary antibody too concentrated |
|
| 2 | Excessive primary antibody binding |
|
| 3 | Detection substrate incubation time too long |
|
| 4 | Insufficient washing |
|
Nonspecific staining of human tonsil tissue stained with anti-CD3 Epsilon antibody
Improved staining of CD3 Epsilon in human tonsil tissue
Nonspecific staining may arise from off-target antibody binding, inadequate blocking, endogenous tissue activity, or detection-system background. Compare the pattern with positive/negative tissue and no-primary controls before attributing the signal to the target.
| S.No. | Possible Cause | Solution |
|---|---|---|
| 1 | Inadequate deparaffinization of the tissue section |
|
| 2 | Unquenched endogenous peroxidase or endogenous biotin in avidin/streptavidin-based detection |
|
| 3 | Insufficient blocking |
|
| 4 | Section dried out |
|
| 5 | Insufficient washing |
|
| 6 | Antibody degradation, contamination, cross-reactivity or off-target binding |
|
| 7 | Excessive primary antibody concentration |
|
Unlock new dimensions of biological insight with multiplex IHC! By examining multiple biomarkers simultaneously, our cutting-edge platform allows you to unravel intricate cellular interactions and gain valuable insights for your research.
A stained section can be misleading in either direction. An unexpected signal may reflect off-target binding or detection-system background, while a missing signal may reflect epitope loss, inadequate retrieval or a true absence of the target. Review control results and the expected tissue localization before interpreting the pattern.
| Pattern | Possible explanation | First check |
|---|---|---|
| Unexpected positive staining | Antibody cross-reactivity, nonspecific reagent binding, endogenous enzyme/biotin activity or staining artifact | Examine negative tissue and no-primary controls separately; review localization and detection chemistry |
| Expected positive tissue stains weakly or not at all | Reagent failure, unsuitable retrieval, fixation damage or an incompatible antibody/detection system | Confirm the positive control and protocol details before increasing antibody concentration |
| Test tissue is negative, but external positive control passes | True low/absent target expression, specimen-specific preanalytic problems or heterogeneous expression | Check the internal positive control, specimen processing history and expected expression |
| Signal appears in an unexpected cell compartment | Technical artifact, antibody cross-reactivity or a biologically altered localization pattern | Compare with validated localization and an alternative control or method when available |
A positive or negative IHC result is not defined solely by staining intensity. Interpretation depends on appropriate controls, expected target distribution and, where relevant, a validated scoring method.
Controls help distinguish a specimen problem from an assay problem. Choose positive and negative tissues appropriate to the target and, whenever possible, include an internal positive cell population in the tested specimen.
| Control observation | What it suggests | Next action |
|---|---|---|
| Known positive tissue and test tissue are both blank | The staining run or detection conditions may have failed | Check retrieval, primary/secondary compatibility, substrate activity and instrument/protocol steps |
| Positive control stains, but test tissue is blank | Target expression may be absent, or specimen-specific processing may have reduced detectability | Check internal positive cells, tissue handling and another section/block where appropriate |
| Known negative tissue stains unexpectedly | Potential off-target antibody binding or assay background | Review antibody validation and concentration; compare negative-reagent and detection-system controls |
| No-primary control shows staining | Signal may arise from the secondary/detection chemistry or specimen background | Inspect blocking, endogenous enzyme/biotin activity and secondary-antibody cross-reactivity |
| Internal positive cells fail within the test specimen | Negative staining in the cells of interest may not be interpretable | Reassess specimen fixation, processing and antigen preservation before interpreting the result |
Control limitation: A no-primary control is useful for detecting background from secondary reagents and the detection system, but it cannot by itself demonstrate that the primary antibody binds only the intended antigen. Use appropriate negative tissue or genetically depleted material, when feasible, together with other validation evidence.
For further details, see 6 IHC Controls You Should Know and IHC Optimization.
Proper specimen preparation is critical to maintaining tissue morphology and preserving target epitopes, setting the foundation for any successful IHC protocol. Depending on whether analysis will be done by fluorescence or light microscopy, the preparation methods can vary.
Tissue must be collected and preserved efficiently to prevent degradation and preserve cell and tissue structure. Two main methods are used:
After dissection, fresh tissue should be rapidly frozen in chilled isopentane to prevent ice crystal formation. Once frozen, it is stored at -80°C until sectioning. Larger tissues may need to be cut into smaller blocks to ensure even freezing.
For FFPE tissues, epitopes may become inaccessible due to fixation. Antigens can be unmasked through:
Both methods aid in restoring antigen accessibility for antibody binding.
Choosing the right antibodies is a critical step in ensuring effective IHC results. The following factors should be carefully considered:
Careful consideration of these factors ensures that antibodies perform optimally, resulting in clear, specific staining and accurate data interpretation.
Maximize your research potential with multiplex IHC, which enables the simultaneous visualization of multiple biomarkers. This advanced technique offers a comprehensive view of cellular interactions, unlocking new avenues for your research.
Learn more about our cutting-edge multiplex IHC solutions.
Learn the basic principle of immunohistochemistry (IHC), including how antibodies bind specifically to antigens in tissue sections for target detection.
Review a step-by-step IHC protocol with a clear workflow and recommended reagents to support successful immunostaining for tissue sections and cell samples.
Explore key IHC optimization tips for antigen retrieval, fixation, and embedding to improve staining quality and experimental consistency.
Learn IHC and ICC/IF sample preparation methods, including preserved tissue handling steps that support high-quality staining results.
Troubleshoot multiplex IF issues such as bleed-through, weak signal, and high background with practical controls and quick checks.
Weak or no staining in IHC usually points to one of four places: the sample, antigen retrieval, primary antibody conditions, or the detection layer.
High background in DAB staining usually shows up as one of three patterns: a global brown/gray haze, edge-darkening, or granular brown speckling.
Learn how to choose fluorophores for multiplex IF based on marker abundance, brightness, and channel planning for cleaner panel design.